TP53 Mutations Confer High Risk in Patients With Myelofibrosis Undergoing HSCT
Researchers sought to determine the impact of TP53 mutations on HSCT outcomes in patients with myelofibrosis.
Diagnosis & Disease Information
Pelabresib With Ruxolitinib Shows Improvements in Patients With JAK Inhibitor-Naïve Myelofibrosis
Researchers sought to determine whether combination therapy with pelabresib and ruxolitinib would lead to improvements in spleen reduction volume in myelofibrosis.
Update on Therapeutic Options for Myelofibrosis
A review of myelofibrosis, including an update on treatment options, was presented at the 2023 ONA Summit.
Momelotinib Found Superior to Danazol for the Treatment of Myelofibrosis
Researchers sought to determine if momelotinib provided better improvements in anemia in patients with myelofibrosis, compared with treatment with danazol.
Ongoing Study Shows Promise for Navtemadlin in Patients With Relapsed/Refractory Myelofibrosis
A new study is investigating the use of navtemadlin in treatment of patients with myelofibrosis relapsed/refractory to JAK-inhibitor therapy.
Incidence and Predictors of Thrombotic Events in Secondary Myelofibrosis
Researchers sought to characterize the incidence and risk factors for thrombotic events in patients with secondary myelofibrosis.
Study Advances Knowledge Base About Children and Adolescents With Myeloproliferative Neoplasms
The researchers uncovered higher-than-anticipated rates of thrombosis, hemorrhage, and transformation in their real-world cohort of MPN patients.
Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
LCL161 Shows Moderately Positive Objective Response Rate in Patients With Myelofibrosis
Researchers sought to determine whether LCL161 would induce a response in patients with myelofibrosis.
Depression Common Among Patients With a Myeloproliferative Neoplasm
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...